Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 10.05%, which has investors questioning if this is right time to ...

David A. Santos, Executive Vice President and Chief Commercial Officer at Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), recently sold a portion of his holdings in the company. According to a recent SEC ...

The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

J. Furey, the Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), recently sold shares of the company's common ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Implementing environmental, social, and governance (ESG) practices has become a non-negotiable prerequisite for any business ...

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...

5086 Arabella Cir: Wp Summit Park LLC to Pickens Sandra; $265,000 5090 Arabella Cir: Wp Summit Park LLC to Gruesser Bob & ...

Implementing environmental, social, and governance (ESG) practices has become a non-negotiable prerequisite for any business ...

First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor "Our Phase 1 study evaluating fostamatinib in patients with sickle cell disease is an ...